Caris Life Sciences, Inc. (CAI) Earnings Call Transcript & Summary

November 4, 2026

NASDAQ US Health Care Biotechnology earnings 72 min

Earnings Call Speaker Segments

Russ Denton

executive
#1

Thank you. Caris Life Sciences put out its financial results earlier today for the quarter that closed on September 30th, 2026. With me from Caris are David Dean Halbert, our Founder, Chairman, and CEO; David Spetzler, our President; Brian Brille, our Vice Chairman and EVP; and Luke Power, our CFO. Before we get started, I want to remind everyone that management will be making forward-looking statements on this call within the meaning of federal securities laws; those statements rest on management's current expectations and carry risks and uncertainties that could make actual results differ materially from what is anticipated. For a discussion of the factors that could affect our future results, please see our SEC filings. We undertake no obligation to update these statements except as required by law; today's call will also include discussion of non-GAAP financial measures, which are adjusted to exclude certain specified items. Reconciliations of these non-GAAP measures to the most directly comparable GAAP measures are provided in today's earnings release. A copy of that, along with today's presentation materials, can be found on our Investor Relations website. I'll now hand the call over to our Founder, Chairman, and CEO, David Dean Halbert. David?

David Dean Halbert

executive
#2

Thanks, Russ, and thank you all for being here. We posted another record quarter, with volume rising 21% to 61,500 cases and revenue climbing 27% to $275 million. What pleases me most about those figures is that they keep coming from a plan. Early in the year, we restructured and grew our sales force and put money into the lab ahead of the demand we anticipated. Since then, we've posted two quarters in a row of acceleration, and the year-over-year volume growth this quarter is the strongest we've reported in more than a year, and we expect that momentum to carry into Q4. Our product pipeline has been handled with that same approach, with four launches completed thus far in the year, and before the year closes we'll bring out number five, Caris Confirm, which is our whole genome MRD assay, and we'll complete the construction of our comprehensive offering spanning the patient journey. To us, comprehensive isn't merely a slogan, and a recent illustration came in September with the release of an updated Caris Assure for therapy selection, which detects therapy-relevant genes at 40,000x depth and takes our RNA reads past 600 million. Our constant refrain is deeper, not cheaper, since what matters for an assay is its depth and breadth, and those qualities allow us to continue advancing the science. In 2018, I made the call to shift this company toward whole exome and whole transcriptome, and out of that came our exome platform — MI Cancer Seek, Caris Assure for therapy selection, and today Caris Assure for monitoring. That same philosophy now guides our next stage as we broaden into whole genome, and it shows in how we're tackling early-stage detection, therapy selection, and MRD. Turning to Caris Detect: back in August I shared that interest was outpacing what I had anticipated, and indeed it has, yet we won't pursue it through excessive spending — we're proceeding carefully. We ran two campaigns nationwide featuring Kevin Costner and Jordan Spieth, and I enjoyed meeting with each of them to talk about their reasons for appearing in our spots, and we'll continue launching these and move into additional markets during Q4 and after. Our upcoming campaign will likewise emphasize teaching the public about performance and comprehension of stage. Catching cancer early matters because that's when it can still be treated, prior to spreading — in other words, stage 1 and 2. Past that point, treatment likely won't work, and unfortunately the tests currently being sold depend on a method known as methylation. Relying solely on methylation won’t succeed in early stages for the majority of cancers, and it’s hard to see the appeal—why choose something like a stool test aimed at a single cancer when a blood draw can screen for more than 50 types? That’s exactly the reason we designed Caris Detect using the whole genome. The test is engineered to find cancer while it remains in those early, treatable phases; we’ll continue advancing it with that objective in mind, and as David will explain shortly, we also plan to keep demonstrating our best-in-class performance by expanding our ACHIEVE program. I feel very good about where we stand. While competitors cut corners on price, we chose to invest further. The strategy we put together is delivering results, and we are paying for all of it from our own resources as we keep tight control of the P&L. Our decision-making will continue exactly as before, guided by what we call the mom rule: if it were my mom, I'd want her to get the most complete answer possible. That's what every patient deserves, and it's the path to making precision medicine a reality. Brian, over to you.

Brian Brille

executive
#3

Thanks, David, and I appreciate everyone being on our Q3 2026 earnings call. For Caris, this quarter set another record and matters enormously for a number of reasons. To begin with, our commercial strategy and the investment behind it are paying off, producing volume growth that keeps accelerating. Beyond that, the MCED rollout is progressing nicely, with significant prospective channel partners who are enthusiastic about Caris Detect's technology — in particular its sensitivity at early stages. We're also announcing that we're entering the MRD and monitoring space, launching Caris Assure therapy response monitoring this quarter; next comes the December launch of Caris Confirm for MRD; with these products launched, we now hold the strongest molecular technology spanning the full cancer care continuum, and we achieved all of it while maintaining growth and profitability. Our commercial strategy and investment program is succeeding and generating results; during Q3, we completed roughly 61,500 clinical cases, a 21% increase year-over-year. That makes two quarters in a row of accelerating growth, rising from 15% in Q1 and 18% in Q2. We anticipate this momentum carrying forward as the commercial platform grows and new sales force members gain experience; on the pipeline side, Caris Detect launched this summer, and Caris Assure therapy response monitoring launched this quarter. Consequently, as slide 4 shows, our platform now covers the whole continuum of care, including therapy selection in tissue and liquid biopsy through MI Cancer Seek and Caris Assure, respectively; therapy selection for hematological cancers through ChromoSeq; Caris Detect for MCED; Caris Assure for monitoring; and Caris Confirm for MRD; we're thrilled about the first assay in our MRD suite, Caris Assure for monitoring. Clinically, monitoring matters greatly because it gives oncologists a quantitative measure of how well treatment is working. The beauty of our technology is that it leverages the very same product platform as the Caris Assure liquid biopsy, using the identical whole exome 23,000-gene platform and the same liquid workflow that our customers already depend on for therapy selection. Repeated blood draws with Assure provide us with a consistent longitudinal view of cancer progression through treatment and will add another valuable dimension to our clinical genomic dataset. Caris Confirm, our tumor-informed whole genome MRD approach, is still on track to launch this September — this December. Our clinical customers are eager for both products to launch across the continuum of care. Our commercial channels give us a lot of leverage, since every MRD product will reach the same institutions, oncologists, and patients who already rely on us for therapy selection. Finally, Caris Detect, our MCED platform, has embodied our founder's vision for a long time, and its recent launch continues to gain momentum. Detect's unique multi-omic approach has produced excellent early-stage sensitivity and is being well received in the market. Talks with channel partners—ranging from digital platforms to concierge medicine groups—are progressing very well. During the third quarter, we rolled out our inaugural consumer campaign with Kevin Costner, and more recently we followed with a second one featuring Jordan Spieth, aimed at boosting awareness about why detecting cancer at an early stage matters and about Caris Detect; we're enthusiastic about our data and studies, and Spetz will walk through that, including the expanded ACHIEVE program. Our approach remains a long-term strategic orientation — building the finest, broadest offerings available in the market, and pursuing that innovation while keeping our financial strength intact. The third quarter was a strong one, with total revenues climbing 27% year-over-year to $275 million. Turning to slide 5, our molecular profiling services pulled in $262.7 million in revenue, which was also a 27% increase and the main driver here. One thing worth flagging: last year's comparable quarter included a sizable amount of true-ups, so if you look at it on a pro forma basis, revenue climbed about 45% versus the prior year. All in all, it was a highly productive quarter, as the highlights on slide 6 show. Strong top-line results, combined with the operating leverage built into our model, continue to produce positive financial outcomes even while we ramp up investments — including 27% revenue growth fueled by a 21% rise in clinical volume and a blended ASP of $4,272, which was up 5% year-over-year. Excluding true-ups, our blended ASP was roughly $4,000, representing a 19% increase. This quarter we made substantial investments while still maintaining discipline in our finances. Our adjusted EBITDA came in at $44.4 million, which represents the sixth quarter in a row of positive adjusted EBITDA, and we achieved a return to GAAP profitability with net income of $15.3 million. So far this year, adjusted EBITDA totals $126.3 million. Our balance sheet continues to be strong, with cash and investments of $769 million at the close of the quarter. We think this financial performance continues to provide us with exceptional strategic flexibility, and that underpins our continued investments in the product pipeline as well as the ongoing expansion of our sales organization. Turning now to commercial performance: the commercial strategy and leadership we established in the first quarter are paying off in a systematic way. Turning to slide 7, you can see that clinical case volume has increased in each quarter of this year — roughly 52,800 cases in Q1, 59,200 in Q2, and approximately 61,500 in Q3 — and year-over-year growth has picked up speed every quarter, going from 15% to 18% to 21%, respectively. We're happy to see that acceleration in both tissue and blood. Our commercial strategy is delivering results, and we anticipate continued acceleration in growth for several reasons. First, the therapy selection market still offers abundant opportunity as cancer centers put systematic precision medicine programs in place. Both the institutions and the individual medical oncologists hold the breadth and depth of Caris product technology—that is, 23,000 genes—in high regard. We anticipate that our recent launch of monitoring and our upcoming launch of MRD will substantially boost both our volume performance and our attractiveness as a strategic partner offering a technologically superior product line across the care continuum. Lastly, our cancer center relationships are exceptionally strong, and continued investment in FTEs will help us activate additional medical oncologists across our expanding product line. On the commercial team investment side, we finished the third quarter with 325 people on the commercial team, compared with 290 at the close of the second quarter and 270 when the first quarter ended. The realignment was completed in January, taking us from 82 territories to 146, and we've kept adding reps within that structure. Generally, it takes a new rep six to nine months before they start getting to full productivity, so the people we've brought on during this year will keep building toward their full contribution for a while yet. We believe our technology platform is unmatched, so we intend to continue this commercial investment plan to deliver this extensive product line to the greatest possible number of medical oncologists and institutions. The digital footprint also keeps expanding. More than 75% of orders arrive via EMR and portal channels, and over 3,500 physicians submit orders straight through the EMR. We are investing in research and studies, and our evidence base now totals over 1,300 publications and manuscripts. Our business model is highly powerful; whenever a clinical case is profiled, our dataset grows larger and stronger. As you can see on slide 8, our dataset has now passed 1.2 million profiled cases, among them over 796,000 whole exomes and 849,000 transcriptomes, with roughly 845,000 matched cases that have clinical outcomes; right now we're assessing AI partners, looking at internal capabilities and external data partnerships alike. We're as excited about what lies ahead as we've ever been. As slide 9 shows, our company's positioning is highly differentiated against enormous market opportunities and demand. The Caris molecular technology offers uniquely powerful breadth and depth, and that's now being extended into new product modalities; we have an innovative go-to-market approach, serving as both a clinical partner and a research partner. For example, the Caris Precision Oncology Alliance currently has 102 sites. Being profitable affords us meaningful strategic flexibility, enabling us to continue investing aggressively. Several exciting and significant catalysts are approaching in the next few quarters that present growth and TAM expansion opportunities: ongoing commercial execution and investment, ASP expansion via Assure, a pioneering position in the MCED market, the recent monitoring launch, and the upcoming MRD launch. I'll now turn the presentation over to Dr. Spetzler. Spetz?

David Spetzler

executive
#4

Thanks, Brian. I'll begin with the two new products, then discuss the foundation model that supports our digital AI platform, followed by our plans to expand the ACHIEVE program for Caris Detect, and finally Interception. All of it connects to David's opening point: deeper, not cheaper. Depth and breadth are what enable us to provide a comprehensive approach throughout the patient journey—from early-stage detection to therapy selection and now monitoring and MRD. On Slide 11, you can see the fourth quarter's two launches side by side. Caris Assure therapy response monitoring, which launched recently, covers patients during therapy. Caris Confirm, launching in December, covers surveillance after treatment. Both are built on platforms we already operate. Monitoring is performed on our whole exome platform. Caris Confirm operates on our whole genome platform, where the initial tissue sample is used to define the signature, followed by blood-based testing. Each has its own evidence base: MONSTAR and our real-world cohort support monitoring, while ENSEMBLE and the real-world cohort support Caris Confirm. Reimbursement efforts are ongoing for both: a MolDx submission is being prepared for monitoring, and a cancer-type-by-cancer-type strategy is in place for Caris Confirm, and I'll discuss each in a bit more detail. Let's start with Caris Assure therapy response monitoring, which recently launched as part of the upgraded Caris Assure platform. For therapy selection, Caris Assure informs the oncologist which drug to choose. When it comes to monitoring, that same whole exome liquid workflow—paired with buffy coat to eliminate clonal hematopoiesis—produces a quantitative tumor fraction, and drawing samples over time lets us classify each patient as achieving a molecular response, remaining stable, or progressing. That readout arrives about four to eight weeks before the scheduled scans. You can see the validation on the slide. Clinical validation covered 124 serial pairs, and among the 90-patient landmark cohort, 96% of those classified as molecular responders—49 of 51—subsequently demonstrated disease control on imaging. For patients classified as molecular progression, the hazard of later radiographic progression was almost ninefold greater than for responders—8.99, or 7.16 following statistical adjustment. In an initial independent real-world group of 1,037 patients, molecular progression shows a 2.35-fold hazard compared with response, and the three categories separate in order. From an analytical standpoint, the assay picks up tumor fractions as low as 0.1%, with precision below 9% CV across lots and runs. Turning to slide 13, Caris Confirm marks our entry into minimal residual disease and is presently slated to launch in December. This is a tumor-informed, whole-genome approach. We sequence both the tumor and a matched normal across the entire genome to establish each patient's tracker set, a tracker search space of about 2.5 billion bases. Those variants are then tracked in serial blood draws on the same whole-genome platform that powers Caris Detect. The pathway is fairly straightforward: you start with a baseline blood draw, using buffy coat along with tumor tissue from surgery, then do tumor-normal subtraction to establish the patient's tracker set, followed by a landmark blood draw three to six weeks post-surgery, and after that surveillance draws every three to four months. That design is what delivers an ultra-low limit of detection. Analytic performance is self-evident, with a minimum positivity threshold of 1.38 parts per million. Intended use covers pan-tumor, stage 1 through 3 solid tumors following curative-intent treatment — a setting in which patients are monitored for years. Much like therapy monitoring, it is a recurring test on infrastructure that already exists. If you look at slide 14, you'll see the engine that sits inside our digital AI platform. The pathology foundation model is called HERO; its training used 248,606 routine H&E slides covering 52 cancer lineages, and 98% of those slides — over 243,000 — also have RNA sequencing together with DNA sequencing and IHCs; that pairing is the genuine asset. Every slide gets its labels from molecular results. Processing runs left to right over the slide. The H&E is scanned at 20x. Tissue is split into tiles about a tenth of a millimeter across, roughly 2,300 for each slide. HERO turns every tile into 3,072 individual numbers — the same for all targets, with no retraining needed; for each target, the model figures out how much each tile matters and combines the tiles into one summary at the slide level. Then three models — one for DNA, one for RNA, and one for IHC — use that single slide to predict 297 alterations, 368 RNA expression levels, and 21 protein stains. Caris' digital AI applications are powered by our model. That's why the pipeline shown on the right — morphological subtype, tumor grading, mutation prediction, treatment response, and survival prediction — is able to move forward quickly. Every one of these is a new head built on the same foundation, trained on data we already have. Let me now move on to Caris Detect. As discussed previously, slide 16 illustrates why we built Caris Detect to combine numerous signals across cell-free DNA and RNA, expanding our shots on goal for each early tumor. On slide 17, ACHIEVE-1, the basis for our commercial launch, demonstrated 99.2% specificity and 60.3% sensitivity in stage 1 and stage 2 cancers — the stages where cure rates are highest. I will provide an update shortly on our planned next readout from ACHIEVE-2. Now, as part of this quarterly update, I will give an update on our ACHIEVE program. This is the clinical evidence program behind Caris Detect, and we are announcing an expansion of it, with four studies under the ACHIEVE name totaling 63,000 patients. You saw the 3,000-patient study, ACHIEVE-1, and that readout landed in the first quarter. Our large-scale validation is ACHIEVE-2, targeting 25,000 participants; enrollment stands at roughly 20,000 patients — 80% of the way — and with sample runs now underway, we expect an interim readout in Q1 2027. ACHIEVE-3 is a prospective trial of 10,000 patients drawn from a high-risk population, in which results are given back to patients together with a repeat Caris Detect at 12 months. ACHIEVE-4, also prospective, covers 25,000 patients in a general-risk population, with results returned there too. Planning is currently underway for both ACHIEVE-3 and ACHIEVE-4. On slide 19, as DDH talked about, we've launched two campaigns for Caris Detect, and each of them directs consumers to Caris Detect, and those will keep being rolled out across markets through Q4 and beyond. Lastly, personalized mutation Interception. We laid out this program on our previous call, and today I'll be brief and concentrate on how the pieces of our platform come together to support it. As a reminder, our personalized vaccine approach rests on capabilities we already operate. Caris Detect identifies the early signal, our sequencing pins down the mutations that inform a personalized vaccine, and serial blood draws monitor whether it is clearing. Slide 21 illustrates the stage where our platform stands out most: selecting the correct mutations. As vaccine targets, we pick solely mutations that are expressed and visible to the immune system, and then we monitor response over time; that is where our dataset does its job. Against a paired biopsy cohort of over 42,000 patients, our ranking model achieves 83.8% positive predictive value and 86.5% for the top-ranked variant per patient; we focus on the mutations most likely to prime a response. Our science is centered on these things: a pair of new products for repeat use on the platform, a foundation model enabling the digital AI portfolio to expand rapidly, broad yet precise detection backed by a larger 63,000-patient evidence program, and a novel Interception strategy—all of it built on the depth-first approach. I'll now turn it over to Luke.

Luke Power

executive
#5

Thanks, David. I'll go through the numbers fairly quickly, since we've already covered some of them. We posted another solid quarter, with total revenue of $275.4 million, an increase of 27% year-over-year, bringing nine-month revenue to $755.2 million, which is up 45% year-to-date. Molecular profiling revenue came in at $262.7 million, up 27%, while pharma research and development services revenue reached $12.7 million, up 37% year-over-year. Given that we've broadened our platform this year with new products and with MRD slated to launch later this quarter, we will shift to reporting total clinical volume only. This matches the way our industry reports, and that's the approach we'll use when we publish preliminary full-year volume in January and provide guidance figures moving forward. That said, I'd like to give a little additional detail about the volume numbers for the current quarter. In the third quarter, clinical therapy selection volume came in at approximately 61,500 cases, which represents a 21% increase compared with a year earlier and exceeds the 20% target we had set for that quarter; Caris Detect is not included in this volume, and we will report its revenue within our pharma research and developmental services line until it grows large enough to be broken out separately together with its volume. Therapy selection is still where most of our volume comes from. Since we realigned sales in Q1, over the last two quarters volume has increased roughly 20% compared with a year earlier, and that momentum gives us confidence as we head into Q4. The mix of therapy selection volume matched what we saw in the previous two quarters, with tissue continuing to account for the largest share. Growth rates versus a year ago picked up for both tissue and blood from the second quarter, and our total growth of 21% was the strongest in more than a year — a tribute to the excellent work our sales and lab teams are doing. Regarding Caris Detect, the early launch has gone well, and we're ramping up promotion—two campaigns are active at present—while adding new markets as we move through Q4 and afterward. On gross margin, it came in at 66% for the quarter, which mirrors the mix effect of a broadening product lineup, and we anticipate a comparable figure in Q4. That likewise shows our emphasis on deeper rather than cheaper, as demonstrated by our recently enhanced Caris Assure assay, which now operates on the Illumina NovaSeq X platform with greater depth and read. Operating expenses totaled $163 million, a rise of $48.1 million versus a year ago and roughly $10 million quarter over quarter. That rise matched what we had anticipated, since we keep putting money into the commercial team, plus more marketing spend for Caris Detect and the development effort behind therapy response monitoring and Caris Confirm. All told, these results gave us GAAP net income of $15.3 million, versus $24.3 million a year ago. For the year to date, net income stands at $14.1 million, compared with a net loss of $150 million across the first nine months of 2025. Adjusted EBITDA was $44.4 million, our sixth consecutive quarter in positive territory, against $51.2 million a year earlier, which again benefited from a larger true-up. Adjusted EBITDA for the year to date is $126.3 million, versus $31.7 million over the same nine months a year ago. Free cash flow came in at negative $39.7 million for the quarter, and that number includes $17.5 million in capital expenditures. That was planned, as we mentioned in August — we tapped the free cash flow generated during the first half to fund the inventory ramp and the initiatives supporting our pipeline. You'll see that reflected in the working capital movements on the balance sheet. Across nine months, free cash flow is negative $10.8 million, and now that the inventory investment is behind us, we expect free cash flow to turn positive in the fourth quarter and for the full year. We closed the quarter with $769.2 million in cash and investments, and during Q3 we bought back roughly $10 million of additional stock under our authorized share repurchase program. On slide 24, we keep showing strong growth in both volume and ASP in our molecular profiling business. Base ASP moved past $3,990, a 19% increase year-over-year, and with prior-period collections included, blended ASP reached $4,272, up 5%. On the reimbursement side, in September we got the preliminary 2027 Clinical Lab Fee Schedule under the PAMA cycle. MI Cancer Seek held at $8,450; Caris Assure, though, rose to $5,250 from $3,650, effective January 1 of 2027, pending the final schedule later this year; that will also help the commercial contracts we've been signing, since they generally price off a percentage of the Clinical Lab Fee Schedule rate. That higher rate should push realized ASP up across the contracted book as we head into 2027, and that's the covered live strategy we laid out last quarter. We've also started receiving commercial plan payments for Caris ChromoSeq. Covered lives now total about 264.4 million for MI Cancer Seek and 134.6 million for Caris Assure, and both figures rose again versus the second quarter. Finally, turning to guidance: given how strong our first nine months have been, we're raising our full-year outlook to roughly $1.04 billion to $1.05 billion, up from $1.03 billion to $1.04 billion, which translates to growth of about 28% to 29%, fueled by molecular profiling revenue. When you set aside prior-period true-ups, that guidance points to fourth quarter growth around 40%, matching the underlying rate we reported this quarter. For the fourth quarter, our reported guidance of $285 million to $295 million is essentially comparable to Q4 of 2025, a period that contained approximately $90 million in true-ups stemming from last year's acceleration related to the FDA approval of MI Cancer Seek. As we look toward Q4, we also expect clinical therapy selection volume to continue rising along the upward path observed across the last two quarters, reaching around 65,000 cases—equivalent to roughly 20% growth across the full year. Our GAAP operating expense outlook now stands at approximately $620 million, up from about $600 million, representing growth of roughly 26%. This increase is deliberate. It supports the bigger commercial team, the marketing efforts for Caris Detect, therapy response monitoring, and Caris Confirm, plus running the R&D samples needed for the ACHIEVE-2 interim readout. We still anticipate positive adjusted EBITDA and positive free cash flow for the full year. Through nine months, adjusted EBITDA already stands at $126.3 million, and we expect free cash flow to turn positive again in Q4, making the full year modestly positive, and all of this while still funding the growth initiatives we just described. That concludes my remarks, so I'll hand things back to the operator and we can begin taking questions. Operator?

Vijay Kumar

analyst
#6

Hey everyone, appreciate you fielding my question, and well done on a solid quarter. Luke, I'll aim this first one at you — you said volumes grew faster in both tissue and blood, but could you expand a little on the pace of that acceleration in each, tissue against blood, and give us similar detail on ASPs, please? What drove that gain — ASPs rose 19%?

Luke Power

executive
#7

Yeah. Vijay, as we noted in our prepared comments, we’re not going to report that as a separate line item moving forward. What I can tell you, though, and what I’m disclosing, is that the mix trend matches what you observed between Q1 and Q2: blood keeps growing and tissue keeps growing. The growth rates rose compared with what we shared last quarter, which is great and consistent with our expectations, and I believe we can keep exceeding on that front as we move through Q4. On the ASP side, things look much like they did last quarter. When you blend it all together, our market access and billing groups keep performing well. We've secured coverage for both Caris Assure and MI Cancer Seek, and that momentum should carry into Q4. Based on the guidance we issued, you're looking at roughly the same neighborhood—about a $4,000 base ASP—which would set a new record for us. All in all, we feel great, and the mix and everything else is tracking right to plan.

Vijay Kumar

analyst
#8

That's useful. Perhaps a broader question. Looking simply at how this year has unfolded, your volumes have picked up speed each quarter, and guidance for the fourth quarter suggests yet another increase, to maybe around 23% plus in clinical volume growth. Given that trajectory and the fact that new tests are launching, should '27 clinical volumes speed up from the 20% levels of '26? Would that be a reasonable assumption?

Luke Power

executive
#9

That is a reasonable assumption. What we aren't doing at present, however, is providing guidance for 2027 volume. The crucial thing for us entering this year was essentially twofold: one was clearly carrying out the expansion in the commercial org, but the second was getting the pipeline out as fast as we could. Since we have unique tests and since they're the most comprehensive, we wanted to finish the year with all of those tests on the market, which is what we're working toward and will achieve — we feel very good about that. I think as we begin looking toward 2027, the crucial thing for us was fixing the therapy selection growth, and we've witnessed acceleration in both tissue and blood this quarter, which is great. It demonstrates the commercial plan is delivering, and then as we move into next year with the rollout of monitoring and with the rollout of Confirm, we'll do that in another disciplined, diligent manner as we work through the reimbursement pathways, but it definitely should contribute on the top line because it's the existing sales force selling the products.

Vijay Kumar

analyst
#10

Thanks.

Subbu Nambi

analyst
#11

Hi, everyone. I appreciate you taking my question. ChromoSeq and MI Clarity each have roughly 2 quarters of commercial history behind them now. Do they factor into the updated guide? How did each one ramp during the quarter, and at what point do they start contributing meaningfully?

Luke Power

executive
#12

Subbu. Those are smaller — clearly a smaller share — and that's the reason I pointed to the mix over the past couple of quarters, but they keep growing, though obviously they aren't at the same scale as what we do with tissue and our blood assays. They'll keep growing as we move through that over the next couple of quarters. The 65,000 cases relates to key therapy selection, and it would include a small portion from them, but not a whole lot. Based on what we reported last quarter and what we're actually disclosing this quarter, I think you'll see that continue to improve, but right now it isn't as big a market as tissue and blood.

Subbu Nambi

analyst
#13

No, Luke, my point was about timing — when do they start making a real contribution? And I have a follow-up as well.

Luke Power

executive
#14

My sense is that as we move toward the close of this year and then into the following one, heme will keep expanding, and MI Clarity will too. At this point, when we consider the guidance for the rest of the year, those two aren't material relative to blood and tissue.

Subbu Nambi

analyst
#15

Okay, understood. I’d frame that as more 27 than the current year. Regarding the enhanced Caris Assure with the track table for response monitoring, you intend to seek MolDx reimbursement for it. At what point do you expect to submit to MolDx, and is the data already in hand, or is it still being generated?

Luke Power

executive
#16

Spetz, do you want to take that one?

David Spetzler

executive
#17

Yes, the trial is done, and we’re now preparing that submission. It ought to take place within the coming several months. We first need to get it published, and predicting how long the publication process will take is always difficult.

Subbu Nambi

analyst
#18

That's reasonable. One final question: in the quarter, what share of blood tests came with tissue tests attached? You've consistently been in the neighborhood of 30, 40%. Should we anticipate the same, or has that attachment rate increased substantially?

Luke Power

executive
#19

We have watched it expand, though likely not in any significant way. It has climbed beyond 40%, sitting at 42% for the third quarter, yet not substantially above that level.

Subbu Nambi

analyst
#20

Perfect. Thanks, everyone.

Derik De Bruin

analyst
#21

Great. I appreciate you taking my questions. I wanted to clarify: Caris Detect now sits in the R&D line, the pharma R&D line. Is that also true for 3Q? And a related question about the 4Q guide — how do you split things between the profiling business and the R&D side? Any assumptions would be great.

Luke Power

executive
#22

Detect will be reported in that line until we have a couple more quarters. That matches what we've generally said before about launches of new products; we'll keep watching it, but once it becomes material — it was minor next to the roughly $275 million we posted — we haven't disclosed it separately yet. We're feeling quite positive about its direction. Looking ahead to Q4, none of the new products are factored in. From a guidance perspective, that's how we'll keep doing it. We prefer to hold off for a couple of quarters before we consider adding further new products into it. Looking at Q4, molecular profiling accounts for roughly $265 million, while pharma contributes somewhere in the $20 million to $30 million range — and none of that reflects Detect.

Derik De Bruin

analyst
#23

That's really useful. So about the MRD launch, I was wondering whether you could say a bit about your reimbursement process — definitely indication by indication, but do you have any timelines in terms of when we'll see reimbursement for the first indication? Thank you.

Luke Power

executive
#24

Do you want to handle that, Spetz, or should I?

David Spetzler

executive
#25

It's fairly similar, honestly. Our initial trial is finished, and we need to get that published in colorectal cancer, after which we'll be in a position to submit to MolDx.

Derik De Bruin

analyst
#26

I suppose around 2027 would be a pretty good time, wouldn't it?

David Spetzler

executive
#27

Yes.

Derik De Bruin

analyst
#28

Thank you.

Adam Wieschhaus

analyst
#29

Thanks for taking my question. You said Assure will shift to the higher CLFS rate in January. I'm just curious how you view the size and timing of that benefit when it comes to realizing ASP in 2027, especially since you've noted commercial contracts are typically priced as a percentage of that CLFS rate. Thank you.

Luke Power

executive
#30

Adam, yes. Honestly, we feel very good about that. It ought to happen quite quickly, particularly regarding the contracts we've already signed, and clearly for Medicare itself as well. During Q1 and Q2, we'd anticipate most of the step-up showing up then; we keep making headway with additional payers where coverage isn't in place at present, and clearly that proposed increase taking effect on January 1 should assist those negotiations too. Our expectation would be an effect across Q1 and Q2, mainly Q1, however.

Adam Wieschhaus

analyst
#31

Thanks. You also said interest in Detect is still running ahead of what you expected, though you don't plan to pursue that demand by spending too much. In what ways are you gauging the response to the first rollout, and how do you decide how aggressively to ramp that investment up?

Luke Power

executive
#32

It's comparable to our general approach, and by disciplined we mean that one of the distinctive situations we enjoy is, clearly, that we are financing every one of these initiatives from our own resources. The negative free cash flow stemmed from a single occurrence, since we made that upfront inventory buy, and our feelings about Detect's progress are very positive. What we're doing is we keep evaluating, clearly, together with our partners, the pull-through, and our sentiment there is good, and we're also continuing to broaden the partnerships, and we will work through that during Q4. In addition, regarding the actual ad campaign, we rolled that out in chosen markets. A full broad launch has not happened yet, and we will keep evaluating it quarter by quarter. A crucial point, which we mentioned on the call for last quarter, is that we remain mindful of the possibility for this test along with the capacity limits surrounding it, so that is the reason we are pursuing the disciplined strategy of rolling it out one market at a time, and we will keep evaluating that as we move toward the end of the year and into next year.

Adam Wieschhaus

analyst
#33

Thanks.

Casey Woodring

analyst
#34

Great, and thanks for taking my questions. So for the first one, could you expand a bit on the MCED launch? And if you're able to be specific, how many MCED tests were sold during the quarter, and what's assumed in the 4Q guidance?

Luke Power

executive
#35

Casey, nothing is assumed in the 4Q guide, and at this point, as we mentioned in the prepared remarks, we're going to keep it within the research line until we see more and more activity flowing through before we break it out. We'll keep evaluating that, but for Q4 there is nothing for it in the guide.

Casey Woodring

analyst
#36

Got it. So if my math is right, pharma R&D revenue in 4Q comes to roughly $20 to $30 million. That would suggest a fairly significant reduction to the full-year figure, I'd imagine. Could you just take us through what you're seeing in the pharma R&D service business as the year wraps up, and what you expect for that business line going forward? Thanks.

Luke Power

executive
#37

Casey, you've been watching the trends since the start of the year. From a revenue perspective, that has also gotten better sequentially. It's a business we clearly haven't concentrated on previously, but traction is starting to build, and one thing we really zeroed in on as we entered the year was steering away from smaller deals toward larger, long-term ones instead, and those sales cycles keep running a bit longer. Heading into Q4, with that guidance, we feel quite good about that stepping up to over 100% growth, and we believe we can sustain that momentum as we keep building out the team into 2027. Overall, I'd say we feel quite good about where our revenue stands on a total basis, and that's why I'm confident, obviously, with the guidance, and that's the reason the only range centers on that pharma, since we have a couple of deals moving through the pipe, and it's really more a matter of timing.

Casey Woodring

analyst
#38

Got it. Thanks.

Albert He

analyst
#39

Hey there, great. Appreciate you taking my question. I might just pick up from where Casey left off regarding MCED. Right now you have that on the pharma R&D side. At what point do you expect MCED volumes to truly scale up? Would that be something like 2028 or 2029, when reimbursement probably kicks in, or what's your thinking on that as we look ahead? Thanks.

Luke Power

executive
#40

No, once more, Albert, with MCED what we're doing is self-pay, direct to consumer, and that differs from what others are doing, since a main reason we're taking that route is we want to be sure it stays centered on the technology. Technology ought to clearly drive the science, and it ought to drive the way you go to market; that's one of the things that sets us apart here compared with all the other approaches out there that are using the same sales force calling on PCP. We do expect it to keep ramping, and once again, that hinges on how fast we choose to put our foot on the gas from a campaign standpoint, and that's where we said during the prepared remarks that we won't overspend by doing this, but we'll do it smartly. We feel really good about where it stands today, and that increased penetration we're seeing, I would expect it to keep ramping through the next couple of quarters. Again, we'll evaluate as we move into 2027 how much we want to spend on the ad campaign, but we're going to be smart about it.

Albert He

analyst
#41

That's useful, thanks. So perhaps to follow up on that. On the previous quarter's call, you said certain sequencing rivals exist that offer greater throughput at a lower cost than the main supplier you're currently using. Is there some kind of switching process underway for you folks — in other words, do you anticipate COGS dropping further as a result, or how are you thinking about COGS from here? Thanks for taking the call.

Luke Power

executive
#42

Well, I certainly believe there's room on the COGS side. As I think we said on an earlier earnings call, we're technology agnostic. In my view, more competition is a good thing, and we keep evaluating. There's certainly opportunity as we move into 2027 and past that, and it will keep declining. Again, what we're focused on at present is building the best technology, not concentrating on cost. You can see that in our upgraded version of Caris Assure. Again, we went deeper rather than cheaper; we could have produced that and boosted the margin, but again, we want to obtain the data, we want to make sure it's the best test available on the market; we always take that approach before we actually begin focusing on the unit economics. I think as we move into 2027 with all our tests on the market, that's when you'll begin to see the benefit flowing through to margin, and we feel quite confident about that no matter which supply vendor.

Albert He

analyst
#43

All right, thanks so much.

Luke Power

executive
#44

Go ahead, Spetz.

David Spetzler

executive
#45

Oh, you can go ahead, Luke. It's fine.

Luke Power

executive
#46

Of course, I really do think we take that into consideration, but as I said a moment ago, our priority is always going to be the technology first, rather than the FDA pathway, so that we can secure reimbursement further down the road. If you make reimbursement the initial focus, I think that could constrain how well your test performs, since you'd be building a test to fit within that particular margin. That's not how we operate, to be clear — the FDA is not something in our near-term future on that front, though we will keep evaluating the broader macro environment as it evolves over the coming couple of years. At present, what we're focused on is, obviously, delivering the ACHIEVE-2 interim readout in Q1 — hopefully early Q1 — and then finishing that study, and after that expanding, as Dr. Spetzler described, with ACHIEVE-3 and ACHIEVE-4, to demonstrate the sustained performance of a whole genome approach, which is unique. I'd say that is more our strategy at the moment around the trials, and we'll evaluate the FDA pathway as we move through that. Understood, and thank you for that color. Then, again on Caris Detect, it was nice to see the ad campaign launch. Just curious whether you have any color on how the launch has been received and, yeah, anything you've heard that speaks to that. The feedback has been positive. Again, it's a unique approach, and I think people appreciate that. That's among the key pieces of feedback we're getting. Performance in stage 1 and stage 2 is obviously the best key metric for any early-stage detection test, and that's why David said in the opening as well that this is our focus. It's early stage, stage 1 and stage 2, where you can make a difference. I think the response to that has been positive. Again, we're being disciplined in how we've rolled it out, and we're going to keep increasing the marketing behind it, but without overspending, as David said at the opening. It's been positive. We'll keep assessing, and then we'll keep monitoring it going forward. Great, thank you, guys.

Dan Brennan

analyst
#47

Great, thanks. Appreciate the questions. I came in a bit late, though I believe I'm up to speed now. Perhaps just regarding the Q4 volume guidance of 65,000, which is consistent. I realize there's a step-up there. You have the expanded sales force, which you must feel good about, but does that figure include some cushion, since this quarter's number came in roughly as you expected on volume, while price was a major upside driver. Just thinking about fourth-quarter volume, how do you feel about it.

Luke Power

executive
#48

We feel very good about it. Naturally we'll guide to what we expect the numbers to be. The 65,000 is the expectation together with that, because it aligns with our plan at the start of the year, which clearly we beat once more by a percentage point in Q3, but we keep evaluating, and we keep believing that 20% is sort of the guide number for now. Certainly, as we move through the quarter, we feel very positive about our volume numbers.

Dan Brennan

analyst
#49

That's a hard one. Thank you, Luke. I believe someone raised a question earlier regarding possible 20% volume growth in '27. I realize you're not providing guidance, but you've also mentioned adopting a cautious approach once you reach the stage of giving guidance. Is there any way to think about whether you'll naturally build in some kind of cushion for next year, or is your view that you'll simply take this year's figure and carry it forward?

Luke Power

executive
#50

We'll evaluate that at year-end. I certainly think we could look at where things stand with the new launches; we feel quite positive about them, particularly monitoring and MRD as they come through the pipeline. I think once we move into next year, that's where our focus will be — alright, what will we guide to from the new products, where do we believe the therapy selection business stands, and assess it in that manner.

Dan Brennan

analyst
#51

Understood. So essentially, if it's a 20 — whatever that figure ends up being — therapy selection will be included alongside those other items. When you put the guide together, will you break therapy selection out separately?

Luke Power

executive
#52

No, I believe our approach will be to keep evaluating it as it expands, but at the outset I think we'll stick with the route we're on at present, which is reporting one overall clinical volume figure.

Dan Brennan

analyst
#53

Understood. All right. You folks didn’t provide an MCED figure this quarter. I’m aware that question came up three or four times, correct? Did anyone actually give a number, or not?

Luke Power

executive
#54

No.

Dan Brennan

analyst
#55

Nope. Well then. That's it, everyone. Many thanks. Much appreciated.

Derik De Bruin

analyst
#56

Thanks very much. I appreciate you fielding my questions. To start, could you walk us through the discussions you've been having with health systems in the run-up to the Confirm MRD launch? Perhaps how much willingness there is on their side to reduce the number of suppliers, given that you offer the complete portfolio of tests, and could you also discuss how the tests perform relative to others in this area and, more broadly, how you see the competitive landscape?

Luke Power

executive
#57

Sure. Brian, would you like to cover the customer angle, and then Spetz?

Brian Brille

executive
#58

Hi Eve, this is Brian. We have very strong and very broad connections with both institutional and individual medical oncologists, and in many respects those ties have moved ahead of the deployment of our technology — whole exome, whole genome, 23,000 genes — across a wider product line. Demand for an MRD/monitoring type of solution is already built in from all of these relationships. For that introduction — I wouldn't even describe it as a launch; I'd frame it as introducing and providing the Caris platform more broadly across those same institutions, the same oncologists, and in certain cases, the same patients. That really excites me. It's going to be beneficial for us when it comes to volumes, and it will also help simply in terms of how we show up as a strategic partner; it slots in nicely with those discussions, whether at the senior leadership ranks of the institutions or with individual medical oncologists. That has me genuinely enthusiastic. The differentiated technology strikes me as extremely exciting, and so does finishing the continuum of care. That's our view of it. To me, it's simply a very natural item for our current sales force to carry. Now, much as was the case with Caris Assure, this will probably sit within the specialty sales team for Assure, which we keep building. Within the investment program we're adding more full-time employees to the sales force, and we're also expanding the specialty team; that effort, I believe, will form part of the commercial-side strategy and investment program too, and all of it should prove extremely beneficial for a range of reasons.

Derik De Bruin

analyst
#59

Great. And then regarding Detect, I know you said the advertising campaigns really only got started in a handful of markets. I suppose when should we expect the full 100% launch of those campaigns to happen, and could you also discuss the worldwide opportunity for Detect compared with the US opportunity, and where you'd anticipate the first demand showing up?

Luke Power

executive
#60

I can handle that one, Eve. What we'll likely do is keep evaluating things as we proceed with the rollout and confirm we have sufficient capacity to run it. Again, it's a differentiated asset and assay, and it's whole genome, so it involves a lot of sequencing. We'll keep evaluating that on the capacity side as we roll out, and that will line up with our marketing approach and with continuing to grow markets there and grow into partnerships there. You're 100% right, obviously, we're concentrated on the US market at present with the digital platforms we're doing, but I think there's a massive opportunity to expand; that isn't in our plan at present for the next couple of quarters. We're concentrated on the US market, but there's certainly opportunity as we reach the end of 2027 to begin looking at additional strategic partners outside of the US.

Brian Brille

executive
#61

Eve, hi, this is Brian. Eve, we've already received considerable inbound interest from big organizations beyond the U.S. in general, and specifically regarding Detect and MCED as well. It shouldn't come as a shock that people are highly interested in longevity, health span, and MCED, along with our technology tied to Caris Detect. Another point I think deserves mention — we've discussed the technology and the campaigns somewhat — but something else we're devoting substantial time and effort toward is channel development. Rather than adopting an individual PCP-style approach, we're instead building strategic relationships with channel partners that frequently have PCPs organized; we're engaging with digital platforms, concierge medicine groups, longevity companies, and so on, and this market is expanding extremely fast, with very substantial membership, and they're seeking a solution. They want the top technology, they want MCED included as part of their overall strategy, and they desire a superior MCED solution to what's on the market today. I believe we, given our early-stage sensitivity, align very well with that. We have numerous conversations underway; every one of them is positive. What's occurring, and to put it more precisely, is that we're cultivating those relationships and we're completing onboarding, correct? Frequently, they have SABs, they have a process, and we're going through onboarding. They're extremely interested in the technology, all of that is progressing, and I would say there's substantial momentum when it comes to onboarding those different channel partners.

Derik De Bruin

analyst
#62

Great, that's really useful. Thanks.

Tycho Peterson

analyst
#63

Hey, thank you. If we focus only on Caris Assure for therapy monitoring, what's the right way to think about the attach rate alongside therapy selection testing? Is there some general rule of thumb you keep in mind while rolling this out — is it 2 to 1? How should we think about that?

Luke Power

executive
#64

Brian, would you like to handle that one?

Brian Brille

executive
#65

Listen, Tycho, that's a really good question; we believe it will end up being fairly substantial, since it's only natural — with all the interest our technology has drawn — to carry things through into monitoring. I don't believe we've got a precise figure for that, but considering how people responded at first and simply the reasoning behind it, we believe that attach rate might turn out to be fairly substantial.

Tycho Peterson

analyst
#66

Alright. Next, one for Luke about margins. I'm just thinking through the pluses and minuses here — you're launching three tests with no reimbursement right from the start. Detect is obviously cash pay, but then there's the Everlywell partnership, where the economics get split. Could you help us feel comfortable about the margin outlook? I know you'd rather not say much about '27, but how do we get confident that rolling these out won't be significantly dilutive to margins?

Luke Power

executive
#67

Again, that comes down to the disciplined approach we'll bring to everything, Tycho. One of the main things we'll keep evaluating is clearly the gains in sequencing technology, which I believe will help — that came up in an earlier question. We're certainly seeing that happen, and we definitely think it will have a favorable effect on our current products and on the new ones too, when it comes to sequencing cost. The second thing, as well, is that we keep executing across the billing and market access teams, and I think with our current products themselves and with the increase to the $5,250 rate for Caris Assure effective January 1, that will also help soften the impact of launching these products without reimbursement, and that's basically our plan — to keep managing it smartly. I don't anticipate a huge deterioration as we go through this, and then I think we could actually see gains in the sequencing technology. Of course, if MRD turns out to be a highly recurring product, you could have a lot of tests right out of the gates, but we'll launch it smartly with select customers and keep rolling it out customer by customer, instead of a broad launch at first, while we work through the reimbursement pathways. It's comparable to what we're doing with monitoring — a similar approach. Again, we'll be smart about it. I don't anticipate massive deterioration at all, though.

Tycho Peterson

analyst
#68

All right, that's all from me. Thanks.

Paige Chamberlain

analyst
#69

Hey, everyone. Really appreciate the time and the question — obviously all of us are quite focused on Detect right now. I'd like to ask one more if that's okay. If I remember right, on the 2Q call there was a remark about current revenue capacity, and I believe it was specifically about Detect, saying $1 billion in revenue capacity, which at a $3,500 ASP works out to roughly 300,000 tests. Do I have that math right, and is that volume figure something we should have in mind as a near-term ballpark? Thanks.

Luke Power

executive
#70

That's the capacity level we're aiming for, Paige. That's what we're pushing toward. You can see it reflected in what we're spending on CapEx. One of the main things we're concentrating on as we roll out Detect — and the other recurring products too — is building up sequencing capacity to back that potential. We don't have it today, but it's what we're driving toward over the coming couple of quarters, and it's what you've been seeing in our CapEx spend across the last couple of quarters.

Paige Chamberlain

analyst
#71

Thanks, and I'll squeeze in one final question. On the sales force expansion, the most recent number I heard for this quarter is 325. Since the figure you originally aimed for, as I recall, was 300, you've got to be happy with how things are going. What I'd really like is some color on the metrics that give you confidence to keep expanding, and is 325 roughly where you stop, or does the hiring continue? Thanks very much.

Brian Brille

executive
#72

Hello, Paige, Brian here. We're very pleased with what we're seeing. There are so many different things. We believe the market is quite favorable; we observe a substantial and expanding TAM, with precision oncology programs being adopted more and more, plus individual medical oncologists simply doing additional profiling. Broadly speaking, our platform offers numerous advantages, ranging from technology to scale. In my view, our channel itself, together with all the relationships, constitutes a massive competitive advantage for us. Since the FTEs had been declining for a period shortly before the IPO, we keep adding headcount, and we are realizing genuine ROI from that, and we foresee no limit to it—we will keep hiring. For instance, our chief commercial officer is organized. Our territory count is set to rise, and we'll be adding more FTEs as well. The market opportunity is clearly still expanding, and given the considerable advantages we hold, there's no justification for holding back on assembling the various components needed to deliver this technology to additional institutions and more oncologists.

Jack Meehan

analyst
#73

Appreciate you fitting me in, guys. I wanted to approach the volume question from another angle. Within those 61,500 tests you reported, could you possibly break out how much of that came from non-therapy selection? I ask because, following up on Dan Brennan's earlier question, when I look at that sequential step-up in 4Q, I'm assuming that reflects expansion, and getting a bit of color on how that's trending would be really useful.

Luke Power

executive
#74

Jack, that's exactly why we made a point of discussing the mix trend from the first couple of quarters — it lines up with that trend. What you observed from Q1 to Q2, and then carrying through all the way to Q3, we expect that same trend to carry on into Q4.

Jack Meehan

analyst
#75

All right. As a separate follow-up question, I wanted to ask about the supplies showing up on the balance sheet. Clearly you stocked up somewhat last quarter, and it appears you did additional stocking this quarter, so the inventory weeks on hand look high. I was wondering about your approach to stocking, the reason behind it, and whether you see that eventually becoming a source of cash.

Luke Power

executive
#76

Once more, it's in preparation for the launches. A key point is clearly that with the Detect launch, we got ready. Another factor as well is that these kits are the very same ones we'll use for ACHIEVE-2 samples, which we've begun running; that's a major focus for us in Q4, getting that interim readout as fast as we can. And then there's the new Assure launch too, which is also on the Nova X platform. What you observed this quarter with inventory, I think, is simply a general step-up. It's fairly consistent with what we did previously ahead of that big ramp-up in Q2. We obviously paid down a good portion of it, and you can see that in the accounts payable. That fell close to $38 million, and that was deliberate. That's why we feel quite confident about being positive free cash flow once again. We don't expect it to be that rampant at year-end.

Jack Meehan

analyst
#77

Thanks, Luke — I appreciate that.

Alex Henderson

analyst
#78

Hi there, Alex Henderson here, calling in for Kyle Mikson. Congrats on the quarter and the recent test launches, and thanks for fielding our questions. To go back to the first question in the Q&A — I understand you plan to give less granular detail moving forward — what are the main factors you'll keep watching as we head into next year, specifically the volume growth of the tissue therapy selection test? In your prepared remarks you said the therapy selection opportunity remains rich. What makes you confident that you can keep growing the base tissue part of this business from here? Might that require more commercial investment? And for the blood side of the therapy selection business, is mid-double-digit year-over-year test volume growth sustainable in the near to medium term, or might we see somewhat of a slowdown? Thanks.

Luke Power

executive
#79

What we've demonstrated, clearly, is the acceleration — that was in our comments — with both accelerating versus Q2, so that was positive. Tissue was clearly accelerating as well, which is roughly what we expected given the investment we're making, along with the reorganization and the realignment. I firmly believe tissue will keep improving through the end of the year. And based on what we're seeing, I firmly believe it can keep improving as we move into next year. From a broader perspective, blood is clearly growing more quickly — it starts from a smaller base — but that growth continues, and it accelerated in Q3 versus Q2. Again, that speaks to the work the sales team has done. As Brian mentioned, we'll keep adding to the sales team. We won't stop at 325; we'll keep adding given what we're seeing in terms of inbounds, orders, and penetration within institutions. We feel great about both as we go forward, but we won't disclose a growth rate for each one separately — it'll be on a total basis.

Alex Henderson

analyst
#80

Thanks. Clearly, you folks have managed quite a bit of innovation in-house, but it's worth pointing out that you're sitting on a sizable cash pile, and that gives you options. Can you expand on your M&A mandate or the criteria you use? Broadly, are you open to buying technology from outside — whether to strengthen what you already offer, maybe things you plan to launch, or products already commercially available — for force-multiplying reasons, or simply to broaden the test menu? Thanks.

Luke Power

executive
#81

Brian, go ahead.

Brian Brille

executive
#82

I was about to add that this market has expanded and is clearly going through consolidation. You're seeing more M&A activity, and I view that as a healthy development, since quite a few of these businesses lack a commercial channel and truly need to find a home—on a standalone basis they have no real viability. There's ample opportunity out there; we haven't pursued it as a tactic for a whole variety of reasons, among them the fact that nothing we've come across struck us as incrementally helpful to us, especially from a technology standpoint. Our founder here is always focused on developing and pioneering this market, and on creating the best technology, and I believe we're going to keep doing that. With that mentality, and with our leadership position with respect to technology, it's simply hard to find things that would be incrementally useful. That holds despite the fact that we have a skill set here, starting with David's experience in building companies through M&A—there's certainly no reluctance or lack of capability; it's simply that, opportunistically, we think we're better off devoting our time, resources, attention to an organic building strategy. It's always a possibility, and if something relevant comes up, we're certainly capable, both with respect to our own human capital as well as our financial capital.

Alex Henderson

analyst
#83

Great. Thank you.

Operator

operator
#84

That brings us to the end of today's conference call. We really appreciate your participation. You're free to disconnect at this time.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Caris Life Sciences, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Caris Life Sciences, Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Caris Life Sciences, Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.